AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.02-2.11 (-1.04%) ▼|SBUX105.29-0.53 (-0.50%) ▼|SCHW109.12-1.26 (-1.14%) ▼|SO88.55-0.22 (-0.25%) ▼|SPG212.04+0.52 (+0.25%) ▲|T25.92-0.28 (-1.05%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN258.26+4.43 (+1.75%) ▲|UBER75.35-0.61 (-0.80%) ▼|UNH397.02-3.92 (-0.98%) ▼|UNP290.81+1.66 (+0.57%) ▲|UPS102.83-0.67 (-0.65%) ▼|USB63.33-0.20 (-0.31%) ▼|V374.25-4.50 (-1.19%) ▼|VZ50.24-0.36 (-0.70%) ▼|WFC89.06-0.14 (-0.15%) ▼|WMT107.63-0.79 (-0.73%) ▼|XOM160.36-1.85 (-1.14%) ▼|AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.02-2.11 (-1.04%) ▼|SBUX105.29-0.53 (-0.50%) ▼|SCHW109.12-1.26 (-1.14%) ▼|SO88.55-0.22 (-0.25%) ▼|SPG212.04+0.52 (+0.25%) ▲|T25.92-0.28 (-1.05%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN258.26+4.43 (+1.75%) ▲|UBER75.35-0.61 (-0.80%) ▼|UNH397.02-3.92 (-0.98%) ▼|UNP290.81+1.66 (+0.57%) ▲|UPS102.83-0.67 (-0.65%) ▼|USB63.33-0.20 (-0.31%) ▼|V374.25-4.50 (-1.19%) ▼|VZ50.24-0.36 (-0.70%) ▼|WFC89.06-0.14 (-0.15%) ▼|WMT107.63-0.79 (-0.73%) ▼|XOM160.36-1.85 (-1.14%) ▼|
28.3 C
New York
Friday, September 4, 2026

Tag: edema

newssourceFORcompanyinformationcontent1releasesmarket

Everads Announces Two Oral Presentations at ASRS 2025, Including Full Clinical Trial Results with Its Novel Suprachoroidal Injector

– Clinical study confirms safety, feasibility, and tolerability of the Everads Injector– – Preclinical data demonstrate the feasibility of in-office, minimally invasive suprachoroidal buckling using...

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey. 

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

- XIPERE Now Approved for Use in Multiple Global Markets -

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius...

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company’s board of directors granted one new non-executive employee 4,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEdema

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers